Skip to content
10-Q

Quarterly Report

Protagonist Therapeutics, Inc PTGX

0001104659-26-055661

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 64.31M sh
Shares Diluted Q1 2026 · Mar 31, 2026 70.49M sh
Shares Diluted Q1 2026 · Mar 31, 2025 62.96M sh
Capex Q1 2026 · Mar 31, 2026 $215K
Capex Q1 2026 · Mar 31, 2025 $545K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$48.94M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $125.36M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $193.71M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $128.39M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $139.65M
Stockholders Equity Q1 2026 · Mar 31, 2026 $655.47M
Stockholders Equity Q1 2026 · Dec 31, 2025 $614.71M
Stockholders Equity Q1 2026 · Mar 31, 2025 $689.05M
Stockholders Equity Q1 2026 · Dec 31, 2024 $675.3M
Current Liabilities Q1 2026 · Mar 31, 2026 $34.55M
Current Liabilities Q1 2026 · Dec 31, 2025 $45.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $41.99M
Total Liabilities Q1 2026 · Dec 31, 2025 $53.48M
Current Assets Q1 2026 · Mar 31, 2026 $613.46M
Current Assets Q1 2026 · Dec 31, 2025 $577.57M
Total Assets Q1 2026 · Mar 31, 2026 $697.46M
Total Assets Q1 2026 · Dec 31, 2025 $668.19M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.05
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.19
Eps Basic Q1 2026 · Mar 31, 2026 $0.06
Eps Basic Q1 2026 · Mar 31, 2025 −$0.19
Sga Expense Q1 2026 · Mar 31, 2026 $13.28M
Sga Expense Q1 2026 · Mar 31, 2025 $11.74M
Rd Expense Q1 2026 · Mar 31, 2026 $46.74M
Rd Expense Q1 2026 · Mar 31, 2025 $35.89M
Net Income Q1 2026 · Mar 31, 2026 $3.78M
Net Income Q1 2026 · Mar 31, 2025 −$11.66M
Operating Income Q1 2026 · Mar 31, 2026 −$3.65M
Operating Income Q1 2026 · Mar 31, 2025 −$19.31M